机构：[1]Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, People’s Republic of China四川大学华西医院[2]Department of Radiation Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, 42 Baiziting, Nanjing 210009, Jiangsu, China.
Molecular targeted therapy for cancer has been a research hotspot for decades. AXL is a member of the TAM family with the high-affinity ligand growth arrest-specific protein 6 (GAS6). The Gas6/AXL signalling pathway is associated with tumour cell growth, metastasis, invasion, epithelial-mesenchymal transition (EMT), angiogenesis, drug resistance, immune regulation and stem cell maintenance. Different therapeutic agents targeting AXL have been developed, typically including small molecule inhibitors, monoclonal antibodies (mAbs), nucleotide aptamers, soluble receptors, and several natural compounds. In this review, we first provide a comprehensive discussion of the structure, function, regulation, and signalling pathways of AXL. Then, we highlight recent strategies for targeting AXL in the treatment of cancer.AXL-targeted drugs, either as single agents or in combination with conventional chemotherapy or other small molecule inhibitors, are likely to improve the survival of many patients. However, future investigations into AXL molecular signalling networks and robust predictive biomarkers are warranted to select patients who could receive clinical benefit and to avoid potential toxicities.
基金：
National Natural Science Foundation of China
(No. 81602492), the National Key Research, Development Program of China
(No.2016YFA0201402) and the National Major Scientific and Technological
Special Project for “Significant New Drugs Development” (No.
2018ZX09733001) and by the Excellent Youth Foundation of Sichuan
Scientific Committee Grant in China (No.2019JDJQ008)
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类|1 区医学
小类|1 区生化与分子生物学1 区肿瘤学
最新[2023]版：
大类|1 区医学
小类|1 区生化与分子生物学1 区肿瘤学
第一作者：
第一作者机构：[1]Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, No. 17, Block 3, Southern Renmin Road, Chengdu, Sichuan 610041, People’s Republic of China[2]Department of Radiation Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, 42 Baiziting, Nanjing 210009, Jiangsu, China.
通讯作者：
推荐引用方式(GB/T 7714)：
Zhu Chenjing,Wei Yuquan,Wei Xiawei.AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.[J].Molecular cancer.2019,18(1):153.doi:10.1186/s12943-019-1090-3.
APA：
Zhu Chenjing,Wei Yuquan&Wei Xiawei.(2019).AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications..Molecular cancer,18,(1)
MLA：
Zhu Chenjing,et al."AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.".Molecular cancer 18..1(2019):153
医学